Alocent brings to the Wiregrass the types of clinical research trials typically only offered in large cities at large oncology centers.
This means less time spent traveling and more time receiving pioneering medical treatments. This way, we stay with you on the journey by keeping it closer to home.
Meet Our Alocent Team:
Current Clinical Trials
If you are a patient who would like to participate in one of the trials listed here, please ask your physician, or call our clinical research coordinator, Dallas King, at (334) 305-0024.
The studies you find available on this page are just the beginning, as Alocent will be hosting more clinical trials in the near future.
Current Clinical Trials Offered By Alocent
Breast Cancer - Stemline Therapeutics, Inc.
This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the recommended phase 2 dose (RP2D) of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.
Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)
Clinicaltrials.gov ID NCT05563220
Sponsor: Stemline Therapeutics, Inc.
Breast Cancer - AstraZeneca
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
ClinicalTrials.gov ID NCT05774951
Lung Cancer - OncoC4, Inc.
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non- small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once every 21 days, for up to 17 cycles in approximately one year.
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitor
Clinicaltrials.gov ID NCT05671510
Sponsor: OncoC4, Inc.